Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
about
Diabetes and cancer: two diseases with obesity as a common risk factorSafety of dipeptidyl peptidase 4 inhibitors: a perspective reviewDetection, evaluation and treatment of diabetes mellitus in chronic pancreatitis: recommendations from PancreasFest 2012Saxagliptin overview: special focus on safety and adverse effectsDipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trialsChronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus.Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes.Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemiaSaxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular dataSafety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus.Emerging gliptins for type 2 diabetes.Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitusIncretin-based therapies in prediabetes: Current evidence and future perspectivesSitagliptin/Simvastatin: a first combination tablet to treat type 2 diabetes and hypercholesterolemia--a review of its characteristicsIncretin therapy--present and future.The risk of pancreatitis with sitagliptin therapy in older adults: a population-based cohort studyAn inhibitory antibody against dipeptidyl peptidase IV improves glucose tolerance in vivoSafety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors.Autophagy deficiency in β cells blunts incretin-induced suppression of glucagon release from α cellsInterpreting adverse signals in diabetes drug development programs.Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls.Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies.Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated.Do GLP-1-based therapies increase cancer risk?Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin.Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.Sitagliptin/metformin fixed-dose combination: in patients with type 2 diabetes mellitus.The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.Sitagliptin: a review.From theory to clinical practice in the use of GLP-1 receptor agonists and DPP-4 inhibitors therapy.Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence.Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.Potential drug interactions associated with treatments for type 2 diabetes and its comorbidities: a clinical pharmacology review.A review of gliptins in 2011.Drug-induced pancreatitis.Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
P2860
Q26822753-741028DB-F444-4462-B6C4-86D692F2E8D2Q26863262-285E07AE-034B-4A3F-82A4-1BF30DA5EA1BQ27007060-C7540685-897C-44DC-A1FF-A17E7C2FFC9FQ28278863-BAD97959-B6D4-4838-9DF9-236E6D1C65BDQ28294225-49961B0B-AFB5-45C1-87F5-A6A4BA09E4EFQ30513617-BC3F2C19-A4BC-4F2F-A171-E79024BE8425Q33412360-2BEE72EA-7D8F-450D-914F-780CE6B6C087Q33562235-E6F0E432-B6BD-4621-A595-9E2ACEF7EE83Q34041974-B1E2568F-B69B-428E-820A-81DA954C97EFQ34128612-B7A3FC02-2092-456F-A3A4-2B8F13537E50Q34135837-A807EE18-ADDA-4654-95A0-70A32E8113DEQ34347884-E3857E94-AFAC-47BB-A5F9-432AE8CC158BQ34496741-68CF5CB1-634A-45CB-AD0B-753948457C0AQ34699191-E86B0CC1-7DA7-4833-86AB-5E68E81B068EQ35100483-22B20C17-8C46-409F-87E8-0976FD0DF3C8Q35760283-EAAECF5C-5E26-43A1-8112-DC04E83D7481Q36064999-94705929-E92B-4349-A05D-5409909C2C2FQ36526318-59D7E84C-68BF-496B-8B4C-50A4AEDDB709Q36883337-09F85DA5-B275-4E30-9802-5A74F70B8E53Q36930354-4031C3AE-2E18-4C18-A5C2-F748F041AA03Q36942266-6079843A-E400-4FBA-9E9D-3965E829E35FQ37193295-424A6C5E-2196-4366-8F4F-3CB925DC9FDDQ37446672-9ED22288-72F2-4E0F-8341-18EBAADD7E99Q37509313-10B24FDF-12FC-4FBA-BCBF-EFF9D6C45900Q37577143-E6952007-EB70-4E86-919E-8D5C4E8BE20FQ37779779-D6E3EBEA-CEC6-4175-BB7E-2823A8B30A5DQ37837059-638B2F56-2F89-419B-8436-C393005D305CQ37841554-51D363F1-78DF-4DDB-9ACC-42775226CAEDQ37864256-265F511F-5C95-4A80-A5AF-D8306A0FAEF4Q37866299-65E88C49-F3D8-4407-8B4E-67337C96A7A8Q37886184-005DFA65-C686-406F-A6D2-AAB6C0CF6CE9Q37900151-EA58D984-6AB6-49B7-A1A6-B9B7C3618EEFQ37900690-F7BAF182-FF5E-470E-B883-A71193F3EF83Q37910902-9583415D-29D2-47A2-BBB2-5ABB038ED6B8Q37929159-D62D04AE-F204-407D-8957-0137BED3D782Q37964751-07B26BA1-7186-4DF8-A871-BBDEF5B6745EQ37965612-C53CD3C7-CC46-4DEB-84A0-EB6F50772D30Q37982301-2DDFC712-0FDD-443B-87CE-30CBC9DA53CDQ37995760-FC488A71-04E8-46F9-B755-2B5CA4090D21Q38004088-30308AFB-83A7-4AB3-9B83-5E83720976C7
P2860
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
@ast
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
@en
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
@nl
type
label
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
@ast
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
@en
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
@nl
prefLabel
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
@ast
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
@en
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
@nl
P2093
P2860
P921
P1476
Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
@en
P2093
B J Goldstein
D E Williams-Herman
K D Kaufman
S V Machotka
P2860
P304
P356
10.1111/J.1742-1241.2010.02382.X
P5008
P577
2010-04-14T00:00:00Z
2010-06-01T00:00:00Z